Table 2.
Baseline Laboratory Results of Patients in the 3 DOAC Groups
| Dabigatran | Rivaroxaban | Apixaban | Normal Range | |
|---|---|---|---|---|
| WBC, /μL | 8297±2889 | 7147±2013 | 6969±1581 | 3800–10 300 |
| RBC, 106/μL | 4.5±0.5 | 4.4±0.6 | 4.2±0.7 | 4.2–6.2 |
| Hematocrit | 0.4±0.04 | 0.4±0.05 | 0.38±0.05 | 0.42–0.52 |
| Hemoglobin, mmol/L | 8.4±1 | 8.4±1.1 | 7.88±1.3 | 8.7–11.2 |
| Platelet count, 103/μL | 226±79 | 236±57 | 239±70 | 150–450 |
| Quick, % | 92±12 | 99±11 | 96±13 | 70–120 |
| INR | 1.1±0.1 | 1.0±0. | 1.0±0.1 | 0.9–1.2 |
| aPTT, s | 27±4 | 26±6 | 27±5 | <40 |
| Anti‐Xa, IE‐aXa/mL | <0.09 | <0.09 | <0.09 | <0.09 |
| Fibrinogen, μmol/L | 9.8±2.3 | 10.1±2.4 | 9.8±2.1 | 5–12.1 |
| D‐dimer, nmol/L | 3.8±4.3 | 4.9±7.7 | 2.7±3.3 | <2.7 |
| Creatinine, μmol/L | 68.6±15.3 | 68.6±15.3 | 76.3±38.1 | 45.8–83.9 |
| GFR, mL/min/kg | 75±17 | 81±19 | 78±31 | >60 |
| Protein total, g/L | 68±7 | 70±7 | 68±7 | 65–85 |
| Albumin, g/L | 40±4 | 41±4 | 39±5 | 34–48 |
| CRP, nmol/L | 142.9±123.8 | 285.7±438.1 | 219.1±342.9 | <47.6 |
| Procalcitonin, μg/L | 0.09±0.04 | 0.10±0.08 | 0.11±0.09 | ≤0.10 |
| AST, U/L | 0.58±0.3 | 0.55±0.2 | 0.65±0.42 | ≤0.83 |
| ALT, U/L | 0.52±0.33 | 0.53±0.3 | 0.6±0.53 | ≤0.83 |
| GGT, U/L | 1.05±1.15 | 0.78±0.6 | 1.15±1.49 | ≤1.00 |
Results are presented in mean±SD. ALT indicates alanine transaminase; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; CRP, C‐reactive protein; DOAC, direct oral anticoagulants; GFR, glomerular filtration rate; GGT, γ‐glutamyl transferase; INR, international normalized ratio; RBC, red blood count; WBC, white blood count.